Hypertension (high blood pressure) was the most common side effect in studies (73% of patients, versus 16% in the placebo group), followed by diarrhoea (67% vs. 17%) and fatigue (67% vs. 35%). Other common side effects included decreased appetite, hypotension (low blood pressure), thrombocytopenia (low blood platelet count), nausea, muscle and bone pain.
Lenvatinib
Tucatinib
Neratinib
Fostamatinib
Lapatinib
Ponatinib
Selpercatinib
Infigratinib